Evidence map›Paper›PMID 38299714›Full record

ArticleJournal of magnetic resonance imaging : JMRI2024

Non-Invasive Tumor Grade Evaluation in Von Hippel-Lindau-Associated Clear Cell Renal Cell Carcinoma: A Magnetic Resonance Imaging-Based Study.

Aryan Zahergivar, Pouria Yazdian Anari, Neil Mendhiratta, Nathan Lay, Shiva Singh, Fatemeh Dehghani Firouzabadi, Aditi Chaurasia, Mahshid Golagha, Fatemeh Homayounieh, Rabindra Gautam and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. State of the art review of AI in renal imaging.Abdominal radiology (New York) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Aryan ZahergivarRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Pouria Yazdian AnariRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Neil MendhirattaUrology Oncology Branch, National Cancer Institutes, National Institutes of Health, Bethesda, Maryland, USA.
Nathan LayArtificial Intelligence Resource, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Shiva SinghRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Fatemeh Dehghani FirouzabadiRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Aditi ChaurasiaUrology Oncology Branch, National Cancer Institutes, National Institutes of Health, Bethesda, Maryland, USA.
Mahshid GolaghaUrology Oncology Branch, National Cancer Institutes, National Institutes of Health, Bethesda, Maryland, USA.
Fatemeh HomayouniehRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Rabindra GautamUrology Oncology Branch, National Cancer Institutes, National Institutes of Health, Bethesda, Maryland, USA.
Stephanie HarmonArtificial Intelligence Resource, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Evrim TurkbeyRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Maria MerinoPathology Department, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Elizabeth C JonesRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Mark W BallUrology Oncology Branch, National Cancer Institutes, National Institutes of Health, Bethesda, Maryland, USA.
Baris TurkbeyArtificial Intelligence Resource, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
W Marston LinehanUrology Oncology Branch, National Cancer Institutes, National Institutes of Health, Bethesda, Maryland, USA.
Ashkan A MalayeriRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-4442-7343
National Institutes of Health · USNational Institutes of Health Clinical Center · US

Funding

Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZIABC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$29.8M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZIABC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.9M
Clinical Nursing and Data Management CoreZIDBC011089 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.4M
CCR Artificial Intelligence ResourceZIHBC012032 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TÜRKBEY, BARIS · 2021 to 2025
$10.1M
Study of Hereditary Renal and Other Familial SyndromesZIABC010696 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MERINO, MARIA · 2009 to 2025
$4.5M
Intramural NIH HHS Z99 CL999999National Institutes of Health, Intramural Research ProgramNIH Clinical Center Research Award for Staff Clinicians (RASCL)
6 · The paper itself

Abstract

backgroundPathology grading is an essential step for the treatment and evaluation of the prognosis in patients with clear cell renal cell carcinoma (ccRCC). PURPOSE: To investigate the utility of texture analysis in evaluating Fuhrman grades of renal tumors in patients with Von Hippel-Lindau (VHL)-associated ccRCC, aiming to improve non-invasive diagnosis and personalized treatment. STUDY TYPE: Retrospective analysis of a prospectively maintained cohort. POPULATION: One hundred and thirty-six patients, 84 (61%) males and 52 (39%) females with pathology-proven ccRCC with a mean age of 52.8 ± 12.7 from 2010 to 2023. FIELD STRENGTH AND SEQUENCES: 1.5 and 3 T MRIs. Segmentations were performed on the T1-weighted 3-minute delayed sequence and then registered on pre-contrast, T1-weighted arterial and venous sequences. ASSESSMENT: A total of 404 lesions, 345 low-grade tumors, and 59 high-grade tumors were segmented using ITK-SNAP on a T1-weighted 3-minute delayed sequence of MRI. Radiomics features were extracted from pre-contrast, T1-weighted arterial, venous, and delayed post-contrast sequences. Preprocessing techniques were employed to address class imbalances. Features were then rescaled to normalize the numeric values. We developed a stacked model combining random forest and XGBoost to assess tumor grades using radiomics signatures. STATISTICAL TESTS: The model's performance was evaluated using positive predictive value (PPV), sensitivity, F1 score, area under the curve of receiver operating characteristic curve, and Matthews correlation coefficient. Using Monte Carlo technique, the average performance of 100 benchmarks of 85% train and 15% test was reported.

resultsThe best model displayed an accuracy of 0.79. For low-grade tumor detection, a sensitivity of 0.79, a PPV of 0.95, and an F1 score of 0.86 were obtained. For high-grade tumor detection, a sensitivity of 0.78, PPV of 0.39, and F1 score of 0.52 were reported. DATA

conclusionRadiomics analysis shows promise in classifying pathology grades non-invasively for patients with VHL-associated ccRCC, potentially leading to better diagnosis and personalized treatment. LEVEL OF EVIDENCE: 1 TECHNICAL EFFICACY: Stage 2.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMagnetic Resonance ImagingNeoplasm GradingAdultAgedFemaleHumansImage Processing, Computer-AssistedMaleMiddle AgedPrognosisRetrospective StudiesROC Curvevon Hippel-Lindau Diseaseclear cell renal cell carcinomafuhrman gradingmachine learningmagnetic resonance imagingradiomicsvon Hipple‐Lindau

Identifiers

PMID38299714
PMCPMC11291699
OpenAlexW4391436852

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.